These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 18788128)

  • 21. Optimizing insulin therapy in patients with type 1 and type 2 diabetes mellitus: optimal dosing and timing in the outpatient setting.
    Hahr AJ; Molitch ME
    Am J Ther; 2008; 15(6):543-50. PubMed ID: 19127139
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of Devices in Insulin Delivery.
    Meneghini LF; McNulty JN
    Diabetes Technol Ther; 2017 Feb; 19(2):76-78. PubMed ID: 28118052
    [No Abstract]   [Full Text] [Related]  

  • 23. Comment on Publications from OpT2mise Study.
    Milenkovic T; Kocova M; Krstevska B; Pemovska G; Smokovski I
    Diabetes Technol Ther; 2016 Jul; 18(7):446-7. PubMed ID: 27043789
    [No Abstract]   [Full Text] [Related]  

  • 24. Re: Empowering patients during insulin initiation: a real-world approach.
    Barbato VA
    J Am Osteopath Assoc; 2010 Jul; 110(7):396-7. PubMed ID: 20693572
    [No Abstract]   [Full Text] [Related]  

  • 25. Psychological insulin resistance in patients with type 2 diabetes: the scope of the problem.
    Polonsky WH; Fisher L; Guzman S; Villa-Caballero L; Edelman SV
    Diabetes Care; 2005 Oct; 28(10):2543-5. PubMed ID: 16186296
    [No Abstract]   [Full Text] [Related]  

  • 26. Diabetes: controlling the insulin balance. The pharmacologic repertoire.
    Flavin K; Haire-Joshu D
    Am J Nurs; 1986 Nov; 86(11):1244-51. PubMed ID: 3535510
    [No Abstract]   [Full Text] [Related]  

  • 27. Insulin-delivery devices.
    Hicks D
    Prof Nurse; 2003 Feb; 18(6):315-6. PubMed ID: 12630241
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Care of people with diabetes in the pharmacy].
    Müller U
    Pharm Unserer Zeit; 2012 Jul; 41(4):313-22. PubMed ID: 22764001
    [No Abstract]   [Full Text] [Related]  

  • 29. Comparison of preference for NovoPen(®) 4 with previous insulin pen treatments after 12 weeks in adult patients with type 1 and type 2 diabetes: a multicenter observational study.
    Israël-Bultman H; Hyllested-Winge J; Kolaczynski M; Steindorf J; Garon J
    Clin Ther; 2011 Mar; 33(3):346-57. PubMed ID: 21600387
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Health economics and compliance of vials/syringes versus pen devices: a review of the evidence.
    Asche CV; Shane-McWhorter L; Raparla S
    Diabetes Technol Ther; 2010 Jun; 12 Suppl 1():S101-8. PubMed ID: 20515297
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Insulin and antidiabetic agents -- the old and the new.
    Golembiewski J
    J Perianesth Nurs; 2006 Apr; 21(2):131-4. PubMed ID: 16600835
    [No Abstract]   [Full Text] [Related]  

  • 32. An Evolutionary Perspective on Basal Insulin in Diabetes Treatment: Basal Insulin in Primary Care.
    Miller EM
    J Fam Pract; 2016 Oct; 65(10 Suppl):S8-S13. PubMed ID: 27846337
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oral insulin: an update.
    Chatterjee S; Bhushan Sharma C; Lavie CJ; Adhikari A; Deedwania P; O'keefe JH
    Minerva Endocrinol; 2020 Mar; 45(1):49-60. PubMed ID: 31347343
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Noninjectable methods of insulin administration.
    Cernea S; Raz I
    Timely Top Med Cardiovasc Dis; 2006 Nov; 10():E29. PubMed ID: 17136235
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Insulin Pumps.
    Pickup JC
    Diabetes Technol Ther; 2017 Feb; 19(S1):S19-S26. PubMed ID: 28192024
    [No Abstract]   [Full Text] [Related]  

  • 36. Inhaled human [rDNA origin] insulin, a novel formulation for diabetes mellitus.
    Pham DQ; Cohen H; Chu V
    J Clin Pharmacol; 2007 Jul; 47(7):890-903. PubMed ID: 17585117
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Beyond insulin: what else might help?
    Scheiner G
    Diabetes Self Manag; 2014; 31(1):30, 32-4. PubMed ID: 24640060
    [No Abstract]   [Full Text] [Related]  

  • 38. [Intensive insulin treatment improves metabolic control and preserves residual insulin secretion at 5 years from the diagnosis of type-1 diabetes mellitus].
    Pérez Maraver M; Gonzálbez Morgaez J; Molina Lacasa A; Fernańdez Castañer M
    Med Clin (Barc); 1998 Dec; 111(19):758. PubMed ID: 9922961
    [No Abstract]   [Full Text] [Related]  

  • 39. [Which treatment can be proposed to a diabetic patient presenting with secondary failure of oral antidiabetics?].
    Blanc MH; Galtier-Dereure F; Parer-Richard C; Bringer J; Jaffiol C
    Rev Med Suisse Romande; 1993 Nov; 113(11):955-61. PubMed ID: 8272722
    [No Abstract]   [Full Text] [Related]  

  • 40. The pathophysiological basis for intensive insulin replacement.
    Rolla A
    Int J Obes Relat Metab Disord; 2004 Sep; 28 Suppl 2():S3-7. PubMed ID: 15306831
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.